A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation. Pierre Fabre is the MA-Holder and AOP Orphan has the distribution right.
Canemes® contains the active ingredient nabilone, a synthetically produced substance belonging to a group of compounds called cannabinoids (derived from cannabis plant). Canemes® prevents nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients